News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The firm's lead product is a blood-based assay, called Alibrex, which uses PCR technology to monitor stage IV solid tumor cancer therapy.
The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.
OmniVis is developing the assay for cholera detection in environmental samples while the lab that created it is working toward a paper-based HIV test.
The team evaluated BSTs from Norgen, Streck, Roche Diagnostics and PreAnalytix, and said Norgen's was the best in terms of genetic material storage.
Cardiac immunoassays paced revenue growth in Q4. The firm also saw an 88 percent jump in total revenues for 2018, supported by 43 percent growth in molecular diagnostics.
